Newlink Genetics Prices Public Offering Of Common Stock

AMES, Iowa, Oct. 03, 2017 (GLOBE NEWSWIRE) — NewLink Genetics Corporation (“NewLink Genetics”) (Nasdaq:NLNK), a late-stage biopharmaceutical company, today announced the pricing of its underwritten public offering of 5,000,000 shares of its common stock at a price to the public of $10.25 per share. All of the shares of common stock to be sold in the offering will be offered by NewLink Genetics. NewLink Genetics has granted the underwriters a 30-day option to purchase up to an additional 750,000 shares of its common stock sold in the public offering on the same terms and conditions.  

NewLink Genetics intends to use the net proceeds from the offering to fund its research and development efforts to further advance its pipeline of product candidates, including the continued clinical development of indoximod, and for working capital and other general corporate purposes.

The offering is expected to close on or about October 6, 2017, subject to satisfaction of customary closing conditions. 

BofA Merrill Lynch and Stifel are acting as joint book-running managers for the offering. Baird is acting as co-manager for the offering. 

A shelf registration statement relating to the shares of common stock offered in the public offering described above was filed with the Securities and Exchange Commission (SEC) on June 25, 2015 and declared effective by the SEC on July 28, 2015. The offering is being made only by means of a written prospectus and prospectus supplement that form a part of the registration statement.A preliminary prospectus supplement and accompanying prospectus relating to the offering has been filed with the SEC and is available on the SEC’s website at  A final prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available on the SEC’s website at Copies of the preliminary prospectus supplement and the accompanying prospectus and copies of the final prospectus supplement and accompanying prospectus, when available, may also be obtained by contacting BofA Merrill Lynch, NC1-004-03-43, 200 North College Street, 3rd floor, Charlotte NC28255-0001, Attn: Prospectus Department, Email: [email protected]; or from Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, CA 94104, or by telephone at (415) 364-2720, or by email at [email protected].

Print Friendly, PDF & Email

Author: Travis Esquivel

Travis Esquivel is an engineer, passionate soccer player and full-time dad. He enjoys writing about innovation and technology from time to time.

Share This Post On

Submit a Comment

Your email address will not be published. Required fields are marked *